All News

Vexas

ICYMI: VEXAS Syndrome - A Review

Jack Cush, MD

Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.

Read Article
guidelines.recommendations.jpg

2026 Guidelines for the Treatment of Axial Spondyloarthritis

ACR

New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children.

Read Article
Biomarker,genes

Where are we with Biomarkers in Rheumatoid Arthritis?

Jack Cush, MD

Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and prognostication have not yet advanced beyond rheumatoid serologies and C-reactive protein (CRP).

Read Article
SPA.spectrum.jpg

Redefining axial spondyloarthritis

Jack Cush, MD

An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."

Read Article
RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
RheumNow Podcast square

Infectious Rheumatology (5.15.2026)

Jack Cush, MD

Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.

Read Article
What’s New in Psoriatic Arthritis: A Whirlwind Tour At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/zN4K92UnW9
Dr. John Cush RheumNow ( View Tweet)
RA-ILD: Screening risk and genetic susceptibility Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development. https://t.co/IABp8NhUtS https://t.co/j8UHK2GRd7

Links:

Dr. John Cush RheumNow ( View Tweet)
Interesting poster #POS0939 from @SteZhao #EULAR2026 Long-term or recurrent antibiotic use in childhood associated w doubled risk of axSpA in HLA-B27+ individuals 11,611 HLA-B27+ UK biobank Recall bias? Yes but self-reported exposure validated with primary care data @RheumNow https://t.co/VmxI3BW6FE

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔮 Can polygenic risk scores predict PsA timing in psoriasis? Another GWAS study (n=703) says YES! 70-SNP model achieves AUC 0.843 for predicting PsA onset <10 vs >10 years #POS0088 #EULAR2026 @RheumNow https://t.co/wI4Jy8Yu2A

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
🧪 Can genetics predict TNFi response in PsA? OUTPASS GWAS (n=329): High BMI, comorbidities & novel XKR4 locus linked to non-response at 6 months #POS0087 #EULAR2026 @rheumnow

Nelly ZIADE 🍀 Nellziade ( View Tweet)

CyTOF reveals significant sexual dimorphism in monocyte populations in active #axSpA Women show reduced classical and non-classical monocytes vs healthy controls. Men do not show the same pattern. Sex is not just a demographic variable in AxSpA it is also an immunological one.

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

ACPA and the Transition from Arthralgia to Rheumatoid Arthritis Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for https://t.co/pCaYdEg1gZ
Dr. John Cush RheumNow ( View Tweet)
♂♀ Does sex matter in #axSpA long-term? GESPIC (n=525,10y): Yes! ♂ less symptoms but 2x more spinal progression #OP0101 #EULAR2026 @RheumNow https://t.co/znFXWyrfZl

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
HLA-Cw6: a marker of more severe and difficult to manage psoriatic arthritis? POS0484 #EULAR2026 @RheumNow https://t.co/MIYZxuYT4v

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
A Practical Approach to Myositis-Specific Antibodies https://t.co/14qow6zhsD

Links:

Rheumatology update aabdogafar ( View Tweet)
PTPN22 1858C>T allele, seen in 5-15% NAmerica, often assoc. w/ autoimmune dz risk. BUT...PNAS shows Ptpn22 augments innate immunity and enhances NK activity against coronavirus infection https://t.co/1AMTuOXtoT https://t.co/9f3JdimJsG

Links:

Dr. John Cush RheumNow ( View Tweet)
True or False: HLA-B27 positivity in psoriatic arthritis is associated with earlier disease onset and a higher prevalence of axial involvement. Put your knowledge to the test in this week's RheumIQ quiz at https://t.co/KVK8J2iaFQ https://t.co/SZZqaNvO2Z

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of Toll-like Receptor Research A new review on TLRs systematically summarizes 40 years of discoveries in the TLR field, from the initial identification of Toll in Drosophila embryonic development to the current understanding of multilayered regulatory mechanisms that https://t.co/Rvy24nmuTj
Dr. John Cush RheumNow ( View Tweet)
HLA-B27 in PsA: assoc w/ earlier onset, axial Dz, enthesitis, systemic inflammation. Study of 333 CASPAR PsA pts - 12% HLA-B27 positive--earlier onset (43 v 49), axial (46 v 24%), enthesitis (33 v 18%). No signif differences in sex, dactylitis, uveitis, Rx responses, https://t.co/ALP6AnygSf
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×